TNF inhibitors for uveitis: Balancing efficacy and safety

Ocular Immunology and Inflammation

Volumn 18, Issue 6, 2010, Pages 421-423

  Cunningham Jr , Emmett T ^a,b   Zierhut, Manfred ^c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

adalimumab; biologics; demyelination; etanercept; infliximab; multiple scleroisis; ocular inflammation

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BETA1A INTERFERON; CERTOLIZUMAB PEGOL; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR;

DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; UVEITIS;

ANTIBODIES, MONOCLONAL; DEMYELINATING DISEASES; HUMANS; OPTIC NEURITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 78649269479     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2010.531176     Document Type: Editorial

References (31)

1. Cunningham ET Jr, Wender JD. Practical approach to the use of corticosteroids in patients with uveitis. Can J Ophthalmol. 2010; 45(4):352-358.
2. Taylor SR, Isa H, Joshi L, Lightman S. New developments in corticosteroid therapy for uveitis. Ophthalmologica. 2010; 224 (Suppl) 1:46-53.
3. Lee FF, Foster CS. Pharmacotherapy for uveitis. Expert Opin Pharmacother. 2010; 11(7):1135-1146.
4. Okada AA. Immunomodulatory therapy for ocular infam-matory disease: a basic manual and review of the literature. Ocul Immunol Infamm. 2005;13(5):335-351.
5. Jabs DA. Treatment of ocular infammation. Ocul Immunol Infamm. 2004; 12(3):163-168.
6. Lustig MJ, Cunningham ET Jr. Use of immunosuppressive agents in uveitis. Curr Opin Ophthalmol. 2003; 14(6):399-412.
7. Smith JR, Rosenbaum JT. Management of immune mediated uveitis. BioDrugs. 2000; 13(1):9-20.
8. Solomon SD, Cunningham ET Jr. Use of corticosteroids and non-corticosteroid immunosuppressive agents in patients with uveitis. Comp Ophthal Update. 2000; 1(5):273-286.
9. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular infammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000; 130(4):492-513.
10. Rosenbaum JT. Future of biological therapy for uveitis. Curr Opin Ophthalmol. 2010; Sep 8. [Epub ahead of print]
11. Hemmati HD, Dunn JP. Biologic therapy for uveitis. Expert Rev Ophthalmol. 2010; 5(2):225-239.
12. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007; 18(6):481-486.
13. Lim L, Suhler EB, Smith JR. Biologic therapies for infam-matory eye disease. Clin Exp Ophthalmol. 2006; 34:365-374
14. Sharma SM, Nestel AR, Lee RWJ, Dick AD. Clinical review: anti-TNF-a therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Infamm. 2009; 17(6):403-414.
15. Deuter CME, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M. Behcet's disease: ocular effects and treatment. Prog Ret Eye Res. 2008; 27:111-136.
16. Lee RWJ, Dick AD. Treat early and embrace the evidence in favour of anti-TNF-a therapy for Behcet's uveitis. Br J Ophthalmol. 2010; 94(3):269-270.
17. Qian Y, Acharya NR. Juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol. 2010 Aug 19. [Epub ahead of print].
18. Sfkakis PP. The frst decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010; 11:180-210.
19. Goldstein DA. Uncovering the risk of immunosuppressive therapy in patients with uveitis. Arch Ophthalmol. 2009; 127(6):799-800.
20. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007; 56(10):3248-3252.
21. Papadia M, Herbort CP. Infiximab induced demyelina-tion causes visual disturbance mistaken for recurrence of HLA-B27 related uveitis. Ocul Immunol Infamm. 2010, Sep 1. [Epub ahead of print]
22. Li SY, Birnbaum AD, Goldstein DA. Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Infamm. 2010, Sep 1. [Epub ahead of print]
23. Maimone D, Gregory S, Arnason BG, Reder AT. Cytokine levels in the cerebrospinal fuid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991; 32(1):67-74.
24. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identifcation of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest. 1991; 87(3):949-954.
25. Selmaj KW, Raine CS. Experimental autoimmune encepha-lomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology. 1995; 45(6 Suppl 6):S44-S49.
26. Cruz Fernández-Espartero M, Pérez-Zafrilla B, Naranjo A, et al.; BIOBADASER Study Group. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum. 2010; Sep 21. [Epub ahead of print]
27. Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol. 2004;22(5 Suppl 35):S134-S140.
28. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996; 47(6):1531-1534
29. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1999; 11;53(3):457-465.
30. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006; 21:1366-1371.
31. Cepeda Ej, Williams FM, Ishimori ML, Weisman MH, Reveille JD. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis. 2008; 67:710-712.